FIELD: medicine.
SUBSTANCE: group of inventions relates to methods for enhancing degradation of improperly packaged proteins and protein aggregates. A composition for the treatment or prevention of a disease or disorder associated with an improperly packaged protein or protein aggregates contains a vector based on an adeno associated virus (AAV) containing a nucleic acid sequence encoding human TRIM11, where the specified disease or disorder is neurodegenerative disease or disorder. A method for the treatment or prevention of a disease or disorder associated with an improperly packaged protein or protein aggregates in a subject who needs it, a composition, and a method for the treatment or prevention of a disease or disorder associated with degradation of a functional mutant protein, where the specified disease or disorder is cystic fibrosis, and a method for obtaining a recombinant protein are also proposed.
EFFECT: enhancing degradation of improperly packaged proteins and protein aggregates.
9 cl, 42 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
